Collins Helen Louise reported option exercise involving 5,000 shares of Enliven Therapeutics, Inc. at $2.48 for $12.4k on Sep 17, 2026

Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
CHIEF MEDICAL OFFICER
CHIEF MEDICAL OFFICER
Filed Sep 21, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
$12,400Shares × reported price
Shares traded
5,000Common Stock
Price per share
$2.48Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
30,000Direct
Trade date
Sep 17, 2026Option exercise
Filed
Sep 21, 2026, 5:22 PM ET4-day reporting delay
Accession
0001701247-26-000013Code M · Transaction 226927
How reported position traded is calculated

Calculated only for code-P purchases and code-S sales.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Sep 17, 2026Option exercise5,000$0.00$0Trade 226931
Sep 17, 2026Sell2,916$50.03−$145,890.98Trade 226928
Sep 17, 2026Sell1,844$50.71−$93,507.21Trade 226929
Sep 17, 2026Sell240$51.48−$12,355.68Trade 226930
5 transaction rows in this filing. Joint filers share the same rows.

ELVN price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
ELVN · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago +20%1w ago +12%1d ago −2.2%
Returns since7d −8.4%30d −17%90d180d1y

Footnotes in full

F1: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025. F2: Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock, subject to the applicable vesting schedule and conditions of each RSU. F3: This transaction was executed in multiple trades at prices ranging from $49.305 to $50.30. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F4: This transaction was executed in multiple trades at prices ranging from $50.3099 to $51.26. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F5: This transaction was executed in multiple trades at prices ranging from $51.365 to $51.675. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F6: These securities are RSUs. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock, subject to the applicable vesting schedule and conditions of each RSU. F7: All of the shares subject to this option are fully vested and exercisable as of the date hereof.